San Diego-based Plexium, a biotech startup focused on discovering and developing protein degrading therapeutics directed towards historically challenging drug targets, announced this morning that it has raised $35M in a financing round. The funding is an extension of the company's October 2019 Series A round. The funding was led by Lux Capital and Pivotal BioVentures, and also The Column Group, DCVC Bio and other curren tinvestors. As part of the funding, it has added Adam Goulburn, Partner at Lux Capital and Rob Hopfner, Managing Partner at Pivotal BioVentures, to its board, with Mike Grey joining as Chariman of the Board; Grey also serves on the boards of BioMarin Pharmaceutical, Mirati Therapeutics, Horizon Therapeutics, and other biotech companies.
Tags
efforts
finds
biotech
35m
Category:
Financial Services
Latest from this category |
|
|
